Thursday, June 25, 2026
🇺🇸 FDA

Regulatory Tools — Patent Term & LOE Planning

Patent Expiry Calculator

Estimate nominal drug patent expiry from filing date, PTA, PTE, pediatric exclusivity, and manual day adjustments. Built for BD/licensing, competitive intelligence, and regulatory affairs teams — not legal or patent advice.

Quick Answer

This patent expiry calculator estimates nominal US utility patent expiry from a non-provisional filing date plus 20 years, then adds PTA, PTE, manual adjustments, and an optional six-month pediatric exclusivity planning overlay. Use it for loss-of-exclusivity triage, generic-entry timing, and BD diligence — not as legal advice. Confirm all dates against USPTO records, FDA Orange Book listings, and patent counsel before licensing or rNPV decisions.

Patent Term Model

Base term

Nominal expiry = filing date + 20 years

Adjustments

Adjusted expiry = nominal expiry + PTA + PTE + manual days

Pediatric option

Planning date = adjusted expiry + 6 months when applicable

Drug Patent Expiry Estimator

Enter official dates and day adjustments from patent or regulatory records.

Base patent term
Term adjustments
Planning options

Estimated adjusted expiry

-

-

Nominal 20-year expiry -
Total adjustment -
Pediatric planning date -
Remaining time -

Confirm against patent file history, official PTA/PTE records, Orange Book listings, maintenance status, terminal disclaimers, and legal review before using the date in loss-of-exclusivity analysis.

How to Use the Patent Expiry Calculator

  1. Enter the effective non-provisional US filing date from the patent record or USPTO PAIR.
  2. Add official PTA days from the issued patent face or file wrapper; add PTE days from the USPTO extension order if applicable.
  3. Use manual adjustment days for counsel-reviewed corrections, terminal disclaimer modeling, or settlement planning.
  4. Select the pediatric exclusivity overlay if modeling a six-month FDA marketing exclusivity extension for planning.
  5. Review adjusted expiry, remaining life, and reconcile with Orange Book listings and patent counsel before LOE or rNPV decisions.

Worked Example

Scenario: Compound patent with non-provisional filing date March 15, 2006; PTA 315 days; PTE 730 days; no pediatric overlay.

Nominal expiry: March 15, 2026 (20 years from filing).

Adjustments: 315 + 730 = 1,045 days ≈ 2 years, 10 months added → adjusted expiry ≈ January 2029.

Next step: Cross-check against Orange Book patent expiry for the listed NDA and model regulatory exclusivity in our Exclusivity Period Calculator.

Pharma & BD / LOE planning context

Loss-of-exclusivity (LOE) timing drives generic erosion curves, revenue forecasts, and licensing deal structure. A simple 20-year estimate is only the starting point — commercial entry may be blocked by later-expiring formulation patents, pediatric exclusivity, Paragraph IV litigation stays, or settlement agreements that delay ANDA approval beyond nominal patent expiry.

BD and competitive intelligence teams pair patent expiry estimates with our Exclusivity Period Calculator to find the latest barrier among listed patents, NCE/orphan exclusivity, and biologic data exclusivity. Stress-test deal economics in the rNPV Calculator using conservative LOE assumptions.

For assets still awaiting first approval, map approval catalysts on our PDUFA Calendar 2026 and estimate review clocks with the PDUFA Date Calculator — PTE eligibility begins only after regulatory review consumes patent life.

Adjustment Inputs Explained

PTA Days added for qualifying USPTO examination delay under 35 U.S.C. § 154(b). Use the official value from the patent record.
PTE Regulatory review restoration for eligible FDA-regulated products under Hatch-Waxman, subject to statutory caps and USPTO extension orders.
Pediatric exclusivity Six-month FDA marketing exclusivity overlay — does not extend the patent term but can delay generic approval when statutory pediatric studies are completed.
Manual days Use for counsel-reviewed corrections, terminal disclaimer modeling, settlement planning, or jurisdiction-specific adjustments.

Evidence & sources

Frequently Asked Questions

For many US utility patents, nominal expiry is estimated as 20 years from the effective non-provisional filing date, before patent term adjustment (PTA), patent term extension (PTE), terminal disclaimers, maintenance-fee lapses, or jurisdiction-specific rules. Provisional filing dates and foreign priority claims can shift the effective filing date in complex families.
Patent term adjustment, or PTA, adds days to a US patent term when USPTO examination delays exceed statutory limits under 35 U.S.C. § 154(b). PTA is calculated from the patent file wrapper and printed on the issued patent — do not guess; pull the official PTA value from USPTO PAIR or the patent face before relying on it in LOE models.
Patent term extension, or PTE, restores part of the patent term lost during FDA regulatory review for eligible human drug, biologic, or medical-device products under the Hatch-Waxman framework (35 U.S.C. § 156). PTE is capped (generally five years total, with a maximum 14-year post-approval term) and requires a USPTO extension order tied to the first permitted commercial marketing or use.
No. Pediatric exclusivity under the Best Pharmaceuticals for Children Act does not lengthen the underlying patent. It adds six months of FDA marketing exclusivity that attaches to listed Orange Book patents and applicable exclusivities when statutory pediatric-study requirements are met — effectively delaying ANDA approval for that period even if the nominal patent has expired.
The FDA Orange Book lists approved drug products with associated patent numbers, expiry dates, and exclusivity codes that generic ANDA filers must certify against. Orange Book patent expiry dates may reflect PTE orders and can differ from a simple 20-year filing-date estimate. Always reconcile calculator output with the current Orange Book listing for the relevant NDA.
The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) created the ANDA pathway for generic drugs and the PTE mechanism for innovators. It links FDA approval timing to patent listings, Paragraph IV certifications, 30-month stays, and 180-day first-filer exclusivity — so the commercial loss-of-exclusivity date often depends on litigation outcomes, not patent math alone.
Patent family priority, continuation practice, terminal disclaimers, PTA corrections, PTE orders, Orange Book delistings, pediatric exclusivity, maintenance fees, settlement agreements, and international filings can all shift the practical LOE date. This calculator provides a planning estimate only; patent and regulatory counsel should confirm dates before ANDA strategy, licensing, or investor disclosures.
An ANDA applicant may seek approval after the relevant Orange Book patent expires or is delisted, unless pediatric exclusivity, regulatory exclusivity, or a valid Paragraph IV stay remains. Paragraph IV filers may challenge patent validity before expiry; successful challenges or settlements can allow earlier entry. FDA cannot approve an ANDA while a listed patent with no certification remains unexpired.
This calculator models US utility patent term only. European patents use a 20-year filing rule with annual renewal fees; SPC extensions may apply post-authorisation. Japan, China, and other jurisdictions have distinct PTA/PTE analogues and regulatory exclusivity schemes. Global LOE planning requires country-by-country patent and data-exclusivity analysis, not a single US filing-date estimate.
Remaining life is the calendar interval between a reference date (default: today) and the adjusted expiry date, including PTA, PTE, manual days, and any pediatric planning overlay you select. The calculator reports years and days remaining; if the reference date is past expiry, it shows elapsed time since the estimate instead.
Yes, for complete LOE analysis. Patent expiry and FDA regulatory exclusivity (NCE, orphan, pediatric, biologic) run on separate clocks. After estimating patent term here, model Orange Book and BPCIA exclusivity windows with our Exclusivity Period Calculator to find the later of patent, regulatory, and pediatric barriers to generic or biosimilar entry.
Patent and exclusivity timing drives revenue tail length, generic erosion assumptions, and milestone triggers in rNPV models. BD and licensing teams stress-test deal value by pairing this expiry estimate with our rNPV Calculator and PDUFA Calendar 2026 for approval catalysts. Use conservative LOE dates in diligence until counsel confirms Orange Book and litigation status.

Related Regulatory Tools

Exclusivity Period Calculator rNPV Calculator PDUFA Calendar 2026 PDUFA Date Calculator Submission Timeline Builder

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.